By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the close of the market on Thursday that sales in the fourth quarter ticked up 3 percent year over year, but fell short of Wall Street estimates.

For the quarter ended Dec. 31, 2011, the company brought in a total of $550.2 million, up from $533.7 million a year ago. Consensus analyst expectations were for $562.1 million.

Sales grew 2.4 percent on a currency-neutral basis, Bio-Rad said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.